Outcome of patients with ductal carcinoma in situ and sentinel node biopsy.

Ann Surg Oncol

Breast Surgery Unit, Department of Gastrointestinal and General Surgery, Helsinki University Central Hospital, Helsinki, Finland.

Published: July 2012

Background: In sentinel node biopsy (SNB), tumor-positive findings, mainly micrometastases and isolated tumor cells (ITC) have been found in up to 8%-16% of patients with pure ductal carcinoma in situ (DCIS) or microinvasive DCIS (DCISM). The prognostic significance of such findings is largely unknown. The aim of this study is to examine the outcome of DCIS and DCISM patients with SNB.

Methods: A total of 280 breast cancer patients with pure or microinvasive DCIS underwent SNB between April 2001 and December 2010 at the Breast Surgery Unit of Helsinki University Central Hospital. Patient, tumor, SNB procedure, and follow-up data were gathered. The median follow-up was 50 months (range 7-123 months).

Results: Altogether, 21 patients had tumor-positive sentinel node findings. Of these, 14 were in pure DCIS patients (1 macrometastasis, 1 micrometastasis, 12 ITC) and 7 in DCISM patients (1 macrometastasis, 2 micrometastases, 4 ITC). Also, 16 patients, 10 with pure DCIS and 6 with DCISM, underwent completion axillary lymph node dissection (ALND). Only 1 of them, a patient with DCISM, had additional tumor positive finding in the ALND. During a median follow-up of 50 months (range 7-123 months) there were 5 local recurrences. One patient with pure DCIS and tumor-negative SNB developed overt axillary metastases and later also distant metastases.

Conclusions: DCIS and DCISM patients do have tumor positive findings, but a majority of these are ITC or micrometastases. In light of this study, these findings do not affect the outcome of DCIS or DCISM patients.

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-012-2287-5DOI Listing

Publication Analysis

Top Keywords

dcis dcism
20
dcism patients
16
sentinel node
12
patients pure
12
pure dcis
12
patients
9
dcis
9
ductal carcinoma
8
carcinoma situ
8
node biopsy
8

Similar Publications

Background: Ductal carcinoma in situ with microinvasion (DCISM) represents 1% of all breast cancer cases and is arguably a more aggressive subtype of ductal carcinoma in situ (DCIS). Preoperative evaluation of DCISM usually relies on core needle biopsy, and non-invasive evaluation methods are relatively limited. This study aims to explore the features of conventional ultrasound (US) and contrast-enhanced ultrasound (CEUS) in DCISM and to analyze the US and clinicopathological predictors of infiltrating components.

View Article and Find Full Text PDF

Rationale And Objectives: The prognosis of ductal carcinoma in situ with microinvasion (DCISM) is more similar to that of small invasive ductal carcinoma (IDC) than to pure ductal carcinoma in situ (DCIS). It is particularly important to accurately distinguish between DCISM and DCIS. The present study aims to compare the clinical and imaging characteristics of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) between DCISM and pure DCIS, and to identify predictive factors of microinvasive carcinoma, which may contribute to a comprehensive understanding of DCISM in clinical diagnosis and support surveillance strategies, such as surgery, radiation, and other treatment decisions.

View Article and Find Full Text PDF

Background: Nodal involvement in ductal carcinoma in situ (DCIS) is rare. In patients with DCIS diagnosis prior to mastectomy, a sentinel lymph node biopsy (SLNB) is usually performed during mastectomy, to avoid the risk of reoperation and the non-identification of SLN subsequently, should there be an upgrade to invasive cancer. We aimed to study the feasibility of omitting SLNB in an under-screened cohort, with mostly symptomatic patients and DCIS diagnosis before mastectomy, by determining the upgrade rate to invasive cancer/ DCIS microinvasion (DCISM) and its associated risk factors.

View Article and Find Full Text PDF

Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.

Int J Cancer

May 2024

Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, China.

Article Synopsis
  • Ductal carcinoma in situ with microinvasion (DCISM) is a complex subtype of breast cancer that poses challenges for accurate diagnosis and prognosis, making it crucial to distinguish it from regular ductal carcinoma in situ (DCIS) for better treatment outcomes.* -
  • Traditional diagnostic methods struggle to identify the presence of myoepithelium in suspicious cancer samples, with no single biomarker proving effective across all cases.* -
  • A new technique using multiphoton microscopy (MPM) allows for rapid and precise diagnosis of DCISM by analyzing fluorescent signals in tissue samples, showing strong agreement with existing myoepithelial staining methods.*
View Article and Find Full Text PDF

Rationale And Objectives: Accurate preoperative differentiation between ductal carcinoma in situ with microinvasion (DCISM) and ductal carcinoma in situ (DCIS) could facilitate treatment optimization and individualized risk assessment. The present study aims to build and validate a radiomics nomogram based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) that could distinguish DCISM from pure DCIS breast cancer.

Materials And Methods: MR images of 140 patients obtained between March 2019 and November 2022 at our institution were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!